Brian Beers is a digital editor, writer, Emmy-nominated producer, and content expert with 15+ years of experience writing about corporate finance & accounting, fundamental analysis, and investing.

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Recursion Pharmaceuticals (NasdaqGS:RXRX) reports positive clinical proof of concept for REC ...

So, you want to get better at those tricky LeetCode Python problems, huh? It’s a common goal, especially if you’re aiming for ...